Deutsche Bank AG lowered its stake in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 94.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 151,083 shares of the company's stock after selling 2,409,201 shares during the quarter. Deutsche Bank AG owned 0.07% of Taysha Gene Therapies worth $261,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. purchased a new position in shares of Taysha Gene Therapies during the fourth quarter worth about $8,650,000. Bank of America Corp DE boosted its holdings in Taysha Gene Therapies by 1,178.9% in the 4th quarter. Bank of America Corp DE now owns 1,710,303 shares of the company's stock valued at $2,959,000 after purchasing an additional 1,576,568 shares in the last quarter. Norges Bank purchased a new stake in Taysha Gene Therapies in the 4th quarter valued at approximately $2,528,000. Avoro Capital Advisors LLC lifted its position in shares of Taysha Gene Therapies by 7.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company's stock valued at $34,600,000 after acquiring an additional 1,349,999 shares during the period. Finally, B Group Inc. acquired a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at approximately $1,670,000. Hedge funds and other institutional investors own 77.70% of the company's stock.
Analysts Set New Price Targets
TSHA has been the subject of several research reports. Chardan Capital lifted their price objective on Taysha Gene Therapies from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Thursday, May 29th. Needham & Company LLC restated a "buy" rating and set a $8.00 price objective (up from $6.00) on shares of Taysha Gene Therapies in a research report on Monday. Cantor Fitzgerald reiterated an "overweight" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Citigroup reiterated an "outperform" rating on shares of Taysha Gene Therapies in a report on Thursday, May 29th. Finally, Canaccord Genuity Group boosted their price target on Taysha Gene Therapies from $9.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $7.57.
Read Our Latest Stock Report on Taysha Gene Therapies
Insider Buying and Selling at Taysha Gene Therapies
In related news, major shareholder Paul B. Manning bought 750,000 shares of the business's stock in a transaction dated Friday, May 30th. The shares were acquired at an average price of $2.75 per share, for a total transaction of $2,062,500.00. Following the purchase, the insider now owns 2,841,704 shares in the company, valued at $7,814,686. This trade represents a 35.86% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.70% of the stock is currently owned by corporate insiders.
Taysha Gene Therapies Stock Up 3.2%
Taysha Gene Therapies stock traded up $0.09 during trading on Thursday, reaching $2.88. 3,569,315 shares of the company's stock were exchanged, compared to its average volume of 3,018,861. The company's 50-day moving average is $2.01 and its two-hundred day moving average is $1.92. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.51 and a current ratio of 5.51. Taysha Gene Therapies, Inc. has a 52-week low of $1.05 and a 52-week high of $4.32. The firm has a market cap of $618.23 million, a price-to-earnings ratio of 4.57 and a beta of 0.90.
Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The firm had revenue of $2.30 million during the quarter, compared to analysts' expectations of $1.48 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. During the same period in the prior year, the company earned ($0.10) EPS. On average, analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.
About Taysha Gene Therapies
(
Free Report)
Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.
See Also
Before you consider Taysha Gene Therapies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Taysha Gene Therapies wasn't on the list.
While Taysha Gene Therapies currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
